Progression-free and overall survival in patients with recurrent GBM treated with Bevacizumab versus Bevacizumab/Lomustine

Autor: Heiland, DH, Masalha, W, Franco, P, Machein, M, Weyerbrock, A
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Zdroj: 66. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC); 20150607-20150610; Karlsruhe; DOCMI.09.04 /20150602/
DOI: 10.3205/15dgnc301
Popis: Objective: Bevacizumab (BEV) is widely used for treatment of patients with recurrent glioblastoma (GBM). Recent studies could not show a positive effect of BEV in first-line therapy of GBM. BEV improved the progression-free-survival (PFS) without prolonging overall survival (OS). Lomustine (CCNU) monotherapy[for full text, please go to the a.m. URL]
66. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Databáze: OpenAIRE